ArticleThe journal of allergy and clinical immunology. In practice2022
COVID-19 Infections and Asthma.
Article in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Global research trends in obesity-related asthma (2004-2023): a bibliometric analysis.Frontiers in nutrition · 2025Pooled it
- Knowledge Mapping of COVID-19 and Asthma/Allergic Rhinitis: A Visual and Bibliometric Analysis.Journal of asthma and allergy · 2025Article
- Impact of SARS-CoV-2 (COVID-19) Infections on Mental Health Diagnoses in Youth With Chronic Illness.JAACAP open · 2024Article
- COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation.Life (Basel, Switzerland) · 2024Article
- Pulmonary Evaluation in Children with Post-COVID-19 Condition Respiratory Symptoms: A Prospective Cohort Study.Journal of clinical medicine · 2023Article
- The Role of Vitamins in the Pathogenesis of Asthma.International journal of molecular sciences · 2023Review
- [The problem of long/post-COVID in expert assessments].Unfallchirurgie (Heidelberg, Germany) · 2023Review
- Adolescent Views on Asthma Severity and Management During the COVID-19 Pandemic.Pediatric allergy, immunology, and pulmonology · 2023Article
- Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong.Respiratory research · 2023Article
- Long COVID outcomes in an asthmatic cohort and its implications for asthma control.Respiratory medicine · 2023Article
- Recent developments in the immunopathology of COVID-19.Allergy · 2023Review
- Chronic Rhinosinusitis and COVID-19.The journal of allergy and clinical immunology. In practice · 2022Review
- Perspectives in Respiratory Infections and the Lung.The journal of allergy and clinical immunology. In practice · 2022Article
- Profile of coronavirus disease enlightened asthma as a protective factor against death: An epidemiology study from Brazil during the pandemic.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19), has infected more than 200 million and led to the deaths of more than 4.3 million people. Although there are known risk factors for severe disease, asthma was initially hypothesized to be a risk factor for severe disease given the association between asthma exacerbations and respiratory viral illnesses in general. Fortunately, clinical outcomes for patients with asthma overall are similar to those for patients without asthma, without convincing evidence that asthma is a risk factor for severe disease. This may be explained in part by the decreasing gradient of angiotensin-converting enzyme-2 receptor from the upper to lower respiratory epithelium and that aeroallergen-sensitized patients with asthma can have up to 50% reduction in angiotensin-converting enzyme-2 receptor expression. Vaccination for patients with asthma is recommended for all without clear contraindications. COVID-19-specific treatment options are available depending on the severity of disease. We caution the use of systemic corticosteroids in patients with asthma not requiring supplemental oxygen given an association with worse outcomes. Postacute COVID-19 syndrome or long-haul COVID does not appear to be more prevalent in the population with asthma, and a multidisciplinary approach to care is a reasonable option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.